ReposiTrak Q1 Earnings Call Highlights

ReposiTrak logo with Technology background
Image from MarketBeat Media, LLC.

Key Points

  • Fiscal Q1 results declined year over year: Revenue fell about 3% to $5.8 million, while net income dropped to $1.5 million and diluted EPS to $0.08. The company cited delayed customer purchasing tied to the FDA traceability deadline extension and a focus on higher-margin recurring revenue.
  • ReposiTrak is expanding its investment in SPAR Group: Agreements are expected to give it approximately 49.99% of SPAR on an as-converted basis, along with preferred shares carrying an 8% cash or 10% in-kind annual dividend. The CEO expects the investment to contribute positively to near-term earnings.
  • Touchless Retail pilots are showing promise: Reported trials delivered sales gains of 17% and nearly 26%, and two pilots have advanced to rollouts. The service is already generating revenue, with a six-figure contribution expected in fiscal Q2.
  • Five stocks to consider instead of ReposiTrak.

ReposiTrak NYSE: TRAK reported lower revenue and profit for its fiscal first quarter of 2027, while executives said an expanded investment in SPAR Group and early results from a joint retail service could support future growth.

Revenue was $5.8 million, down approximately 3% from a year earlier but up about $200,000 from the preceding quarter. CFO John Merrill attributed the year-over-year decline primarily to an extension of the Food and Drug Administration’s traceability compliance deadline, which shifted the timing of some customer purchasing decisions, as well as the company’s emphasis on higher-margin recurring revenue.

Net income fell to $1.5 million from $1.8 million, and diluted earnings per share declined to $0.08 from $0.09. Operating income was $1.7 million, compared with $1.9 million a year earlier, while operating margin narrowed to approximately 29% from 32%.

SPAR transaction expands economic interest

ReposiTrak has entered definitive agreements expected to give it approximately 49.99% of SPAR’s outstanding equity on an as-converted common stock basis, before any warrant exercise. Merrill emphasized that the figure represents the expected position under the agreements, not ReposiTrak’s ownership at the September 30 quarter-end.

Under the transaction, ReposiTrak will exchange its existing SPAR common shares and convert the $4 million principal of a SPAR note into a new class of preferred stock. The preferred shares carry a quarterly dividend calculated at an annual rate of 8% if paid in cash or 10% if paid in kind, or a proportional combination. ReposiTrak will also receive warrants and has agreed to provide SPAR with a new $1.5 million revolving credit facility.

The facility carries an 8% annual interest rate and a 24-month maturity. Merrill said there had been no advances under it as of November 16 and that the initial preferred stock exchange and note conversion would not require a new cash payment.

Chairman and CEO Randy Fields said SPAR would remain a separately traded public company. He added that ReposiTrak had helped SPAR reduce annual operating expenses by approximately $7 million and saw potential for further savings. Fields expects the increased investment to contribute positively to ReposiTrak’s earnings in the near term.

Early retail trials show sales gains

The companies are working together on Touchless Retail, which combines ReposiTrak’s technology with SPAR’s field personnel. Fields said ReposiTrak has agreements for approximately 20 pilots, with more in the pipeline, and that two pilots have progressed to rollouts.

Fields said an initial engagement with a dairy distributor produced a 17% sales increase, compared with the 5% increase the company and customer had hoped for. A second test involving greeting cards produced a nearly 26% increase, he said.

Touchless Retail is already generating revenue, and ReposiTrak expects a six-figure contribution in its fiscal second quarter, with growth thereafter as rollouts proceed, Fields said. He added that the partnership is introducing ReposiTrak to retailers it had not previously served and creating opportunities to sell additional services to existing customers.

Fields also identified Touchless Traceability as a potential growth driver. He said the FDA’s compliance deadline had been extended to June 2028 and that ReposiTrak was beginning to receive more inquiries as customers prepare for the requirements.

Cash and capital allocation

ReposiTrak ended September with approximately $24.5 million in cash and cash equivalents and no bank debt. It also held a SPAR investment with a carrying value of $6.8 million and the $4 million note receivable.

Merrill said the company did not repurchase common shares or redeem preferred shares during the quarter because it was prioritizing the SPAR expansion. Approximately $6 million remained under its $21 million authorized common-stock buyback plan at quarter-end.

Fields said the company generally targets a minimum cash balance of around $25 million, while weighing repurchases, preferred-share redemptions and further investment in SPAR. Merrill said the company still needs approximately $12 million in cash to run the business.

Looking ahead, Fields said he expects fiscal 2027 to be another year of growth, with revenue increasing sequentially through the year.

About ReposiTrak (NYSE:TRAK)

ReposiTrak, Inc. provides cloud-based software for managing supply-chain processes, compliance and food traceability. Its platform serves businesses across the food industry, including retailers, wholesalers, distributors, manufacturers and suppliers. The company's offerings include tools for supplier management, food safety and regulatory compliance, supply-chain visibility, and product traceability. Its network helps trading partners share information and track food products through the supply chain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ReposiTrak Right Now?

Before you consider ReposiTrak, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ReposiTrak wasn't on the list.

While ReposiTrak currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines